Experts from industry and the U.S. Food and Drug Administration (FDA) recently joined forces to take a closer look at
Continue reading »
Home ยป
New combination therapy offers bowel cancer patients extra treatment option
Based on scientific findings of the Netherlands Cancer Institute, a new combination treatment has been developed for patients with metastatic
Continue reading »
Preclinical data shows combination immunotherapy could stop liver cancer growth
Even as overall cancer incidence and mortality decrease in the United States, the number of people diagnosed with liver cancer
Continue reading »
Combination drug targeting opioid system may help relieve symptoms of major depression
Two clinical trials of an investigational drug that targets the opioid system support its safety and effectiveness in reducing symptoms
Continue reading »
Novel combination therapy promotes wound healing
By incorporating a gene-suppressing drug into an over-the-counter gel, researchers at Albert Einstein College of Medicine and their colleagues cut
Continue reading »
Researchers to test novel drug combination against toughest breast cancers
Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the
Continue reading »
Amateur weight-lifter develops heart disease after using powerful combination steroid
An amateur weight-lifter developed a serious heart condition after using a powerful combination (anabolic-androgenic) steroid, reveal doctors, writing in the
Continue reading »
Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Combination Approved for Previously Treated MSI-H/dMMR Metastatic Colorectal Cancer
PRINCETON, N.J.– July 11, 2018 (BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy
Continue reading »
Researchers find combination can enhance ipilimumab immunotherapy
Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint
Continue reading »
TLR9 agonist CMP-001-pembrolizumab combination shows early efficacy for metastatic melanoma resistant to anti-PD-1
A combination of CMP-001, an intratumoral Toll-like receptor 9 (TLR9) agonist, and pembrolizumab (Keytruda), tested in patients with metastatic melanoma
Continue reading »